MedTrace Logo

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

NCT02413320 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2021-05-10

Study results available
· View outcomes & findings →

Summary

Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.

Conditions

  • Triple-negative Breast Cancer

Interventions

DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Doxorubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

Sponsors & Collaborators

  • Priyanka Sharma

    lead OTHER

Principal Investigators

  • Priyanka Sharma, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-02-01
Completion
2020-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413320 on ClinicalTrials.gov